Cover story
-
2012 gets a new deal
February 7, 2013, Volume 6 / Number 5
SciBX's second annual global analysis of public-private partnerships and early stage venture financing activity reveals that government institutions are taking a significant role in forming and funding PPPs, and California-based companies are leading the way in PPP activity.
- Read more
-
-
Analysis
Zelboraf dosing rework
NIBR and UCSF researchers have shown that altering the dosing regimen of Zelboraf can prevent the development of drug resistance in mouse models of melanoma. The team will now test an intermittent Zelboraf dosing regimen in patients with melanoma.
Rejuvenating T cells
Two Japanese teams have used iPS cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. Megakaryon is developing the technology of one group to produce iPS cell–derived human T cells.
Sequencing single B cells
University of Texas researchers have developed a high throughput method for sequencing individual B cell immunoglobulin receptors that keeps the link between their paired heavy and light variable chains intact. The next step is modifications to increase throughput and accuracy.
-
Distillery: Therapeutics
